Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Goldman

Showing results (271-280 of 305) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung CancerMichael R Shafique, Terrence L Fisher, Elizabeth E Evans, et al.
The New England Journal of Medicine|September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerYi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S Herbst, Yi-Long Wu, Thomas John, et al.
Leukemia|June 3, 2026
Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemiaAmanda M Li, Catherine Aftandilian, Colleen Annesley, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Nature Communications|June 11, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
Cell|February 2, 2024
Xist ribonucleoproteins promote female sex-biased autoimmunityDiana R Dou, Yanding Zhao, Julia A Belk, et al.
Nature Communications|November 15, 2016
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
Pageof 31

Showing results (271-280 of 305) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung CancerMichael R Shafique, Terrence L Fisher, Elizabeth E Evans, et al.
The New England Journal of Medicine|September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerYi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S Herbst, Yi-Long Wu, Thomas John, et al.
Leukemia|June 3, 2026
Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemiaAmanda M Li, Catherine Aftandilian, Colleen Annesley, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Nature Communications|June 11, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
Cell|February 2, 2024
Xist ribonucleoproteins promote female sex-biased autoimmunityDiana R Dou, Yanding Zhao, Julia A Belk, et al.
Nature Communications|November 15, 2016
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
Pageof 31